The deal adds to Prague-based Zentiva’s continuing organic growth, reinforcing its commercial footprint in Bulgaria, Poland and Romania expanding its presence into additional new markets including Croatia, Hungary, Kazakhstan, Russia, Ukraine and the Western Balkans, the company said.

“With this acquisition, we bring together two of the leading branded generic and OTC businesses in the CEE region,” said Nick Haggar, chief executive of Zentiva.